Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;8(2):e56813.
doi: 10.1371/journal.pone.0056813. Epub 2013 Feb 20.

Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice

Fiorenzo Santoleri  1 , Paola Sorice, Ruggero Lasala, Rosa Carmela Rizzo, Alberto Costantini
Affiliations

Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice

Fiorenzo Santoleri et al. PLoS One. 2013.

Abstract

Introduction: The aim of this study is to evaluate adherence and persistence of patients treated with Imatinib, Nilotinib or Dasatinib, also giving economic evaluations on therapy costs for Received Daily Dose (RDD).

Materials and methods: In this retrospective study, we took into account 3 years from 1st Jan. 2009 to 31st March.2012. Treatment adherence was quantified utilizing ratio between RDD and PDD (Prescribed Daily Dose). Persistence is reckoned taking into account the actual therapy days, comparing posology with supplied dose, drawing the graph using Kaplan-Meir method.

Results: Adherence results in values between 0.8 and 1.0 for Nilotinib (Adh = 0.93), Imatinib (Adh = 0.83) and Dasatinib (0.85). Imatinib has better persistence, 90% of patients in treatment exceed one year of treatment versus 83.3% for Nilotinib and 80% for Dasatinib. The cost per single day of treatment (cost per RDD) was € 39.41 for Imatinib, € 113.60 for Nilotinib and € 94.84 for Dasatinib.

Conclusion: Patients with CML have a loose of adherence both in first line with Imatinib and in second line of therapy with Dasatinib and Nilotinib. Loss of adherence remains a big problem and could be minimized by a patient-oriented project invlolving physicians, nurses, pharmacists and caregiver.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Medication adherence for Imatinib, Nilotinib and Dasatinib.
Figure 2
Figure 2. Kaplan Meier Representation of Persistence to one year of therapy with Imatinib, Nilotinib and Dasatinib.
Figure 3
Figure 3. Kaplan Meier Representation of Persistence to 18 months of therapy with Imatinib.
See this image and copyright information in PMC

References

    1. Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, et al. (2011) Safe Handling of Oral Chemotherapeutic Agents in Clinical Practice: Recommendations From an International Pharmacy Panel. J OncolPract. Jan 7(1): 7–12. - PMC - PubMed
    1. Cassidy J, Douillard J-Y, Twelves C, McKendrick JJ, Scheithauer W, et al. (2006) Pharmacoeconomic analysis of adjuvant oral capecitabinevs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer. April 24 94(8): 1122–1129. - PMC - PubMed
    1. Bartel SB (2007) Safe practices and financial considerations in using oral chemotherapeutic agents. Am J Health Syst Pharm. 2007 May 1 64(9 Suppl 5)S8–S14. - PubMed
    1. Schwappach DL, Wernli M (2010) Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature. Eur J Cancer Care (Engl). May 19(3): 285–92. - PubMed
    1. Foulon V, Schöffski P, Wolter P (2011) Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. ActaClin Belg. 2011 Mar-Apr 66(2): 85–96. - PubMed

MeSH terms